Maternal Serum S100-B, PAPP-A and IL-6 levels in severe preeclampsia

Simple item page
dc.contributor.authorArtunc-Ulkumen B.
dc.contributor.authorGuvenc Y.
dc.contributor.authorGoker A.
dc.contributor.authorGozukara C.
dc.date.accessioned2024-07-22T08:12:56Z
dc.date.available2024-07-22T08:12:56Z
dc.date.issued2015
dc.description.abstractAim: We aimed to investigate the relationship of maternal serum levels of S100-B, PAPP-A and IL-6 with severe preeclampsia. Materials and methods: This prospective case–control study consisted of 27 severe preeclamptic and 36 healthy singleton pregnancies. The groups were matched for parity, maternal age and body mass index. Maternal blood sampling for S100B, PAPP-A and IL-6 was performed at the morning after an overnight fasting. Results: S100-B concentrations were significantly higher in severe preeclampsia group (0.09 ± 0.05 vs. 0.13 ± 0.01 µg/L; p = 0.025). PAPP-A levels were higher (196.54 ± 21.56 vs. 208.80 ± 23.97 mIU/ml; p = 0.707) and IL-6 levels were lower in severe preeclamptic group (68.79 ± 29.89 vs. 37.30 ± 6.46 pg/ml; p = 0.372). AUC value for S100-B was calculated as 0.712. When cutoff level for serum S100-B for predicting severe preeclampsia was regarded as 0.0975 µg/L, sensitivity and specificity were found to be 81.4 % and 58.3 %, respectively. Pregnancies with ≥0.0975 µg/L S100-B levels had 12.75-fold increased risk for having CNS symptoms (OR 12.75; 95 % CI 2.69–60.28) and 3.27-fold increased risk for having HELLP syndrome (OR 3.27; 95 % CI 0.62–17.36). Conclusion: Our results suggest that serum S100B levels may be a potential marker in severe preeclampsia for the severity of hypoperfusion both in placenta and brain pointing at subsequent risk of organ failure. © 2015, Springer-Verlag Berlin Heidelberg.
dc.identifier.DOI-ID10.1007/s00404-014-3610-0
dc.identifier.issn09320067
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16231
dc.language.isoEnglish
dc.publisherSpringer Verlag
dc.subjectAdult
dc.subjectBiological Markers
dc.subjectCase-Control Studies
dc.subjectFemale
dc.subjectHELLP Syndrome
dc.subjectHumans
dc.subjectInterleukin-6
dc.subjectPlacenta
dc.subjectPre-Eclampsia
dc.subjectPregnancy
dc.subjectPregnancy-Associated Plasma Protein-A
dc.subjectProspective Studies
dc.subjectS100 Calcium Binding Protein beta Subunit
dc.subjectSensitivity and Specificity
dc.subjectYoung Adult
dc.subjectbiological marker
dc.subjectinterleukin 6
dc.subjectpregnancy associated plasma protein A
dc.subjectprotein S100B
dc.subjectS100B protein, human
dc.subjectadult
dc.subjectblood
dc.subjectcase control study
dc.subjectfemale
dc.subjectHELLP syndrome
dc.subjecthuman
dc.subjectmetabolism
dc.subjectpathology
dc.subjectpathophysiology
dc.subjectplacenta
dc.subjectpreeclampsia
dc.subjectpregnancy
dc.subjectprospective study
dc.subjectsensitivity and specificity
dc.subjectyoung adult
dc.titleMaternal Serum S100-B, PAPP-A and IL-6 levels in severe preeclampsia
dc.typeArticle

Files

Collections

Scopus Koleksiyonu